aldosterone has been researched along with Hyperparathyroidism, Primary in 12 studies
Hyperparathyroidism, Primary: A condition of abnormally elevated output of PARATHYROID HORMONE due to parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. It is characterized by the combination of HYPERCALCEMIA, phosphaturia, elevated renal 1,25-DIHYDROXYVITAMIN D3 synthesis, and increased BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this study was to assess the effect of 4 weeks of maximally tolerated mineralocorticoid receptor antagonist therapy with eplerenone on PTH levels in patients with primary hyperparathyroidism (P-HPT) when compared to amiloride and placebo." | 9.69 | Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo-controlled randomized trial. ( Brown, JM; Heydarpour, M; Mannstadt, M; Parksook, WW; Turchin, A; Vaidya, A, 2023) |
| "Cross-sectional data of the single-center "Eplerenone in Primary Hyperparathyroidism" trial were used." | 7.83 | Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial. ( Belyavskiy, E; Brandenburg, VM; Brussee, H; Catena, C; Fahrleitner-Pammer, A; Gaksch, M; Grübler, MR; März, W; Meinitzer, A; Perl, S; Pieske, B; Pilz, S; Scharnagl, H; Sechi, LA; Tomaschitz, A; Van Ballegooijen, AJ; Verheyen, N; Wetzel, J, 2016) |
| " The objective of this study was to assess the effect of 4 weeks of maximally tolerated mineralocorticoid receptor antagonist therapy with eplerenone on PTH levels in patients with primary hyperparathyroidism (P-HPT) when compared to amiloride and placebo." | 5.69 | Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo-controlled randomized trial. ( Brown, JM; Heydarpour, M; Mannstadt, M; Parksook, WW; Turchin, A; Vaidya, A, 2023) |
| "Primary hyperparathyroidism is associated with an increased cardiovascular morbidity and mortality." | 5.35 | Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. ( Alrasheedi, S; Ayav, A; Bresler, L; Brunaud, L; Caillard, C; Germain, A; Mirallie, E; Rancier, M; Weryha, G; Zarnegar, R, 2009) |
| "Cross-sectional data of the single-center "Eplerenone in Primary Hyperparathyroidism" trial were used." | 3.83 | Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial. ( Belyavskiy, E; Brandenburg, VM; Brussee, H; Catena, C; Fahrleitner-Pammer, A; Gaksch, M; Grübler, MR; März, W; Meinitzer, A; Perl, S; Pieske, B; Pilz, S; Scharnagl, H; Sechi, LA; Tomaschitz, A; Van Ballegooijen, AJ; Verheyen, N; Wetzel, J, 2016) |
| "Primary aldosteronism (PA) is the most frequent cause of secondary arterial hypertension." | 2.52 | Parathyroid Gland Function in Primary Aldosteronism. ( Asbach, E; Bekeran, M; Reincke, M, 2015) |
| "Studies in primary aldosteronism, congestive heart failure, and chronic kidney disease have identified associations between hyperaldosteronism, hyperparathyroidism, and bone loss, which appear to improve when inhibiting the RAAS." | 2.50 | Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. ( Brown, JM; Vaidya, A, 2014) |
| "In the setting of primary aldosteronism, renal and faecal calcium loss triggers increased PTH secretion which in turn aggravates aldosterone secretion and CV damage." | 2.48 | Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. ( Drechsler, C; Fahrleitner-Pammer, A; Horina, JH; Kienreich, K; März, W; Ofner, M; Pieber, TR; Pieske, B; Pilz, S; Ritz, E; Tomaschitz, A, 2012) |
| "Primary hyperparathyroidism is associated with an increased cardiovascular morbidity and mortality." | 1.35 | Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. ( Alrasheedi, S; Ayav, A; Bresler, L; Brunaud, L; Caillard, C; Germain, A; Mirallie, E; Rancier, M; Weryha, G; Zarnegar, R, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Parksook, WW | 1 |
| Heydarpour, M | 1 |
| Brown, JM | 2 |
| Turchin, A | 1 |
| Mannstadt, M | 1 |
| Vaidya, A | 2 |
| Karwacka, I | 1 |
| Kmieć, P | 1 |
| Kaniuka-Jakubowska, S | 1 |
| Pisowodzka, I | 1 |
| Fijałkowski, M | 1 |
| Sworczak, K | 1 |
| Dobreva, EA | 1 |
| Bibik, EE | 1 |
| Eremkina, AK | 1 |
| Ajnetdinova, AR | 1 |
| Nikankina, LV | 1 |
| Malysheva, NM | 1 |
| Mokrysheva, NG | 1 |
| Castellano, E | 1 |
| Pellegrino, M | 1 |
| Tardivo, V | 1 |
| Attanasio, R | 1 |
| Boriano, A | 1 |
| Borretta, G | 1 |
| DeCarlo, KE | 1 |
| Agrawal, N | 1 |
| Asbach, E | 1 |
| Bekeran, M | 1 |
| Reincke, M | 1 |
| Verheyen, N | 1 |
| Fahrleitner-Pammer, A | 2 |
| Pieske, B | 2 |
| Meinitzer, A | 1 |
| Belyavskiy, E | 1 |
| Wetzel, J | 1 |
| Gaksch, M | 1 |
| Grübler, MR | 1 |
| Catena, C | 1 |
| Sechi, LA | 1 |
| Van Ballegooijen, AJ | 1 |
| Brandenburg, VM | 1 |
| Scharnagl, H | 1 |
| Perl, S | 1 |
| Brussee, H | 1 |
| März, W | 3 |
| Pilz, S | 3 |
| Tomaschitz, A | 3 |
| Rajput, R | 1 |
| Bhansali, A | 1 |
| Bhadada, SK | 1 |
| Behera, A | 1 |
| Mittal, BR | 1 |
| Sialy, R | 1 |
| Khandelwal, N | 1 |
| Brunaud, L | 1 |
| Germain, A | 1 |
| Zarnegar, R | 1 |
| Rancier, M | 1 |
| Alrasheedi, S | 1 |
| Caillard, C | 1 |
| Ayav, A | 1 |
| Weryha, G | 1 |
| Mirallie, E | 1 |
| Bresler, L | 1 |
| Cavalier, E | 1 |
| Ritz, E | 2 |
| Kienreich, K | 1 |
| Horina, JH | 1 |
| Drechsler, C | 1 |
| Ofner, M | 1 |
| Pieber, TR | 1 |
3 reviews available for aldosterone and Hyperparathyroidism, Primary
| Article | Year |
|---|---|
Interactions between adrenal-regulatory and calcium-regulatory hormones in human health.
Topics: Aldosterone; Cardiovascular Diseases; Female; Humans; Hyperaldosteronism; Hyperparathyroidism, Prima | 2014 |
Parathyroid Gland Function in Primary Aldosteronism.
Topics: Aldosterone; Calcium; Homeostasis; Humans; Hyperaldosteronism; Hyperparathyroidism, Primary; Parathy | 2015 |
Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Chronic Disease; Heart Failure; Hemodynamics; Humans; | 2012 |
1 trial available for aldosterone and Hyperparathyroidism, Primary
| Article | Year |
|---|---|
Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo-controlled randomized trial.
Topics: Aldosterone; Amiloride; Calcium; Cinacalcet; Eplerenone; Female; Humans; Hyperparathyroidism, Primar | 2023 |
8 other studies available for aldosterone and Hyperparathyroidism, Primary
| Article | Year |
|---|---|
Improvement of hypertension control and left-ventricular function after cure of primary hyperparathyroidism.
Topics: Adult; Aged; Aldosterone; Blood Pressure Monitoring, Ambulatory; Female; Humans; Hypercalcemia; Hype | 2023 |
[Dynamic changes of renin-angiotensin-aldosterone system parameters after surgery of primary hyperparathyroidism].
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Calcium; Humans; Hyperparathyroidism, Primary | 2020 |
Aldosterone Secretion in Patients With Primary Hyperparathyroidism Without Arterial Hypertension.
Topics: Aldosterone; Humans; Hyperparathyroidism, Primary; Hypertension; Renin-Angiotensin System; Retrospec | 2021 |
Double hit! A unique case of resistant hypertension.
Topics: Adrenal Glands; Aldosterone; Diuretics; Female; Humans; Hyperaldosteronism; Hyperparathyroidism, Pri | 2017 |
Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.
Topics: Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2016 |
A pilot study on hypothalamo-pituitary-adrenocortical axis in primary hyperparathyroidism.
Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; Animals; Dexamethasone; Female; Glucocorticoids; Hu | 2009 |
Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Antihypertensive Agents; Calcium; Cardiovas | 2009 |
Aldosterone and parathyroid hormone: a complex and clinically relevant relationship.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Disease Models, Animal; Female; Humans; Hyperaldoster | 2010 |